Members only

Username:

Password:
International Liver Cancer Association (ILCA)
Avenue de Tervueren, 300
B-1150 Brussels
Belgium
info@ilca-online.org
+32 (0)2 789 2345
+32 (0)2 743 1550

Joint meetings

As part of its objective to advance liver cancer research and care worldwide, ILCA regularly engages into collaborations with key scientific associations to organize joint sessions at their events.

Past initiatives include the following multidisciplinary international joint meetings:

CIRSE-ILCA Collaborative Symposium at ECIO (April 08, Florence, Italy)

Blending Interventional Radiology and Molecular Medicine in HCC
  • Epidemiology and Diagnosis of Hepatocellular Carcinoma
  • Interventional Radiology and Molecular Medicine
EASL-ILCA Joint Workshop at EASL Liver Meeting (April 08, Milan, Italy)
Hepatocellular Carcinoma : Current Changes in Research and Practice
  • Pathogenesis of HCC : the Fibrosis Connection
  • Genomic Profiling and Prognosis : Are the Data There?
  • HCC Origin : Hepatocyte vs Stem Cell
  • Current Challenges in Surgical Therapy
  • Current Evidence Based Practice and Research Trial Design
  • Transition from Past Failure to Emerging Active Therapies
ILCA-ILC Joint workshop (15 June 2008, Hong Kong)
Treatment for Advanced HCC
  • Medical Treatment of HCC
  • Molecular targeted therapies for HCC: from bench to clinic
ACCR-ILCA Special Session at ACCR Annual Meeting (April 09, Denver, USA)
Hepatobiliary Cancer
  • Identification of Driver Genes in Human HCC
  • Role of miRNAs in Human HCC
  • Tumor Dormancy and Oncogene Addiction in HCC
  • Diagnosis and Treatment of Human HCC in the New Millennium
JSH-ILCA Session at 3rd Kobe International Liver Symposium on HCC (June 09, Kobe, Japan)
Integrating Research and practice in Hepatocellular Carcinoma
  • Basic Session : Genomics and Signaling Pathways in HCC
  • Clinical Session : Evidence-based Diagnosis and Treatment of HCC
APASL - ILCA Symposium at APASL conference (March 2010, Beijing, China)
  • Treatment Algorithm of HCC
  • On the Frontier of Molecular Targeted Therapy for HCC
  • Molecular Targeted Therapy in China
  • Prevention of HCC in Chronic Viral Hepatitis
EASL-ILCA Joint Symposium at EASL liver Meeting (April 10, Vienna, Austria)
New advancements in HCC research
  • miRNA: targets for therapies and markers for HCC outcome prediction
  • Integrative molecular classification of HCC
  • Systematic review of loco-regional therapies in HCC
  • Emerging drugs in phase I/II clincial trials in HCC
CIRSE-ILCA Collaborative Symposium at ECIO (July 10, Florence, Italy)
Diagnosis and treatment of hepatocellular carcinoma: ongoing challenges
  • When is biopsy needed and image not enough? Novel pathology criteria
  • HCC staging, evaluation of treatment efficacy and detection of recurrence 
  • Surgery and interventional radiology: competitors or complementary
  • Is radiotherapy back for the treatment of HCC?

Conference

Membership

ILCA – an International and Multi-disciplinary Association for Liver Cancer Experts
Find out more about ILCA Member Benefits and how to become a member.

Association

Mission
The International Liver Cancer Association (ILCA) aspires towards advancing research in the pathogenesis, prevention, and treatment of liver cancer.